Dalidnetug is a humanized monoclonal antibody that targets human β-amyloid precursor protein (APP). By specifically binding to APP, Dalidnetug reduces the production of β-amyloid (Aβ), thereby demonstrating activity in clearing β-amyloid. This compound holds potential for research in Alzheimer's disease.